Novel Quercetin Glycosides as Potent Anti-MRSA and Anti-VRE Agents
Abugafar M.L. Hossion and Kenji Sasaki
Pages 198-205 (8)
Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics
and at least 23,000 people die each year as a direct result of these infections (Threat report 2013). Vancomycin is
an FDA approved antibiotic and is growing importance in the treatment of hospital infections, with particular emphasis on
its value to fight against methicillin-resistant Staphylococcus aureus (MRSA). The increasing use of vancomycin to treat
infections caused by the Gram-positive MRSA in the 1970s selected for drug-resistant enterococci, less potent than
staphylococci but opportunistic in the space vacated by other bacteria and in patients with compromised immune systems.
The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completely novel
classes of antibacterial agents. This paper reports the recent patent review on the strategy for finding novel quercetinglycoside
type antibacterial agents against vancomycin-resistant bacterial strains.
Antibacterial, cell penetration, multidrug-resistant, quercetin, quercetin-O-glycosides, vancomycin.
The University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA 15218, USA.